Adenosine, inflammation pathways and therapeutic challenges

Joint Bone Spine

Volumn 78, Issue 1, 2011, Pages 4-6

  Csóka, Balázs ^a   Haskó, György ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Adenosine; Inflammation; Methotrexate; Rheumatoid arthritis; Spinal cord injury

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; APADENOSON; CD31 ANTIGEN; METHOTREXATE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ANTIINFLAMMATORY ACTIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; INFLAMMATION; LOW DRUG DOSE; NEUROPROTECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REPERFUSION INJURY; RHEUMATOID ARTHRITIS; SPINAL CORD INJURY; SPINAL CORD ISCHEMIA; VASODILATATION;

ADENOSINE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; SPINAL CORD INJURIES;

EID: 78651092071     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.08.010     Document Type: Editorial

References (20)

1. Csoka B., Himer L., Selmeczy Z., et al. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J 2008, 22:3491-3499.
2. Nemeth Z.H., Bleich D., Csoka B., et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 2007, 21:2379-2388.
3. Hasko G., Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 2008, 83:447-455.
4. Nemeth Z.H., Leibovich S.J., Deitch E.A., et al. Adenosine stimulates CREB activation in macrophages via a p38 MAPK-mediated mechanism. Biochem Biophys Res Commun 2003, 312:883-888.
5. Csoka B., Nemeth Z.H., Virag L., et al. A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood 2007, 110:2685-2695.
6. Hasko G., Csoka B., Nemeth Z.H., et al. A(2B) adenosine receptors in immunity and inflammation. Trends Immunol 2009, 30:263-270.
7. Chan E.S., Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002, 4:266-273.
8. Cronstein B.N. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005, 57:163-172.
9. Montesinos M.C., Desai A., Delano D., et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003, 48:240-247.
10. Baharav E., Bar-Yehuda S., Madi L., et al. Anti-inflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 2005, 32:469-476.
11. Szabo C., Scott G.S., Virag L., et al. Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998, 125:379-387.
12. Hasko G., Linden J., Cronstein B., et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008, 7:759-770.
13. Hasko G., Cronstein B.N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004, 25:33-39.
14. McAdoo D.J., Robak G., Xu G.Y., et al. Adenosine release upon spinal cord injury. Brain Res 2000, 854:152-157.
15. Herold JA, Kron IL, Langenburg SE, et al. Complete prevention of postischemic spinal cord injury by means of regional infusion with hypothermic saline and adenosine. J Thorac Cardiovasc Surg 1994, 107:536-541. [discussion 41-2].
16. Cassada D.C., Tribble C.G., Young J.S., et al. Adenosine A2A analogue improves neurologic outcome after spinal cord trauma in the rabbit. J Trauma 2002, 53:225-229. [discussion 9-31].
17. Reece T.B., Okonkwo D.O., Ellman P.I., et al. Comparison of systemic and retrograde delivery of adenosine A2A agonist for attenuation of spinal cord injury after thoracic aortic cross-clamping. Ann Thorac Surg 2006, 81:902-909.
18. Cassada D.C., Tribble C.G., Long S.M., et al. Adenosine A2A analogue ATL-146e reduces systemic tumor necrosing factor-alpha and spinal cord capillary platelet-endothelial cell adhesion molecule-1 expression after spinal cord ischemia. J Vasc Surg 2002, 35:994-998.
19. Cassada D.C., Tribble C.G., Kaza A.K., et al. Adenosine analogue reduces spinal cord reperfusion injury in a time-dependent fashion. Surgery 2001, 130:230-235.
20. Reece T.B., Kron I.L., Okonkwo D.O., et al. Functional and cytoarchitectural spinal cord protection by ATL-146e after ischemia/reperfusion is mediated by adenosine receptor agonism. J Vasc Surg 2006, 44:392-397.